Oncotarget

Research Papers:

2'-Hydroxyflavanone: A novel strategy for targeting breast cancer

Jyotsana Singhal, Lokesh Nagaprashantha, Shireen Chikara, Sanjay Awasthi, David Horne and Sharad S. Singhal _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:75025-75037. https://doi.org/10.18632/oncotarget.20499

Metrics: PDF 1075 views  |   HTML 2595 views  |   ?  


Abstract

Jyotsana Singhal1,*, Lokesh Nagaprashantha1,*, Shireen Chikara1, Sanjay Awasthi2, David Horne1 and Sharad S. Singhal1

1Department of Molecular Medicine, Beckman Research Institute of City of Hope, Comprehensive Cancer Center and National Medical Center, Duarte, CA 91010, USA

2Department of Medical Oncology, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA

*Authors contributed equally to this work

Correspondence to:

Sharad S. Singhal, email: ssinghal@coh.org

Keywords: breast cancer, 2'-hydroxyflavanone, RLIP76, VEGF, xenografts

Received: June 22, 2017     Accepted: July 12, 2017     Published: August 24, 2017

ABSTRACT

Breast cancer is the most common cancer in women that is driven by cross-talk with hormonal and cellular signaling pathways. The natural phytochemicals, due to broad-spectrum anti-inflammatory and anti-cancerous properties, present with novel opportunities for targeting breast cancer. Intake of citrus fruits is known to reduce the risk for incidence of breast cancer. Hence, we tested the efficacy of citrus flavonoid 2'-hydroxyflavanone (2HF) in breast cancer. 2HF inhibited survival, clonogenic ability, cell cycle progression and induced apoptosis in breast cancer cells. 2HF also decreased VEGF levels and inhibited migratory capacity of breast cancer cells. Administration of 2HF led to regression of triple-negative MDA-MB-231 tumors in the mice xenograft model. 2HF decreased the levels of RLIP76 both in vitro studies and in vivo MDA-MB-231 xenograft model of breast cancer. Western blot and histopathological analyses of resected tumors showed a decline in the levels of survival and proliferation markers Ki67, pAkt, survivin, and cell cycle proteins CDK4 and cyclin B1. 2HF treatment led to inhibition of angiogenesis as determined by decreased VEGF levels in vitro and angiogenesis marker CD31 in vivo. 2HF reversed the pro-/anti-apoptotic ratio of BAX/BCL-2 by decreasing anti-apoptotic protein BCL- 2 and increasing pro-apoptotic proteins BAX and BIM in vivo. 2HF also decreased the mesenchymal markers vimentin and fibronectin along with causing a parallel increase in pro-differentiation protein E-cadherin. Collectively, the ability of 2HF to decrease RLIP76, VEGF and regulate critical proliferative, apoptotic and differentiation proteins together provides strong rationale to further develop 2HF based interventions for targeting breast cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 20499